NDUFB9: A Potential Drug Target and Biomarker (G4715)

Target Name: NDUFB9

NCBI ID: G4715

NDUFB9

NDUFB9: A Potential Drug Target and Biomarker

NADH:ubiquinone oxidoreductase (NADH Oxidase) subunit B9, or NDUFB9, is a protein that plays a crucial role in the electron transport chain of the cell's mitochondria. It is a key enzyme in the production of NADH, which is a crucial co-factor for many cellular processes, including energy metabolism and antioxidant response. The function of NDUFB9 is highly conserved across various species, and its role in cellular metabolism has been extensively studied.

In recent years, the study of NDUFB9 has also focused on its potential as a drug target and biomarker. The ability of NDUFB9 to generate NADH, which can be used as a source of electrons for cellular metabolism, has led to the idea that targeting this enzyme may be a promising strategy for treating various diseases.

NDUFB9 and Its Role in Electron Transport

NDUFB9 is a member of the subfamily of NADH:Cytaa3 subunits, which are involved in the production of NADH from NAD+. The NADH produced by NDUFB9 is then used to generate ATP through the process of oxidative phosphorylation. This process is critical for maintaining cellular energy homeostasis and is a central component of the cell's energy metabolism.

The electron transport chain is a critical component of the NADH Oxidase enzyme complex. In this chain, NAD+ is transformed into NADH by the transfer of a electrons from the cytochrome c6 complex to the cytochrome c3 complex. NDUFB9 is a key component of this chain, and its activity is required for the production of NADH.

The Role of NDUFB9 in Cellular Metabolism

The production of NADH by NDUFB9 is closely linked to cellular metabolism and energy homeostasis. NADH is a critical co-factor for many cellular processes, including the production of ATP, the citric acid cycle, and the electron transport chain. It is also involved in the production of NAD+, which is used for the production of ATP by the citric acid cycle.

In addition to its role in energy metabolism, NADH has also been shown to play a crucial role in the regulation of cellular processes, including cell signaling, DNA replication, and stress response. NADH has also been shown to have a neuroprotective effect, and is often used in the treatment of neurodegenerative diseases.

The Potential of NDUFB9 as a Drug Target

The ability of NDUFB9 to generate NADH has led to the idea that targeting this enzyme may be a promising strategy for treating various diseases. One of the key advantages of targeting NDUFB9 is its central role in the production of NADH, which can make it an effective target for diseases that are caused by the defect or dysfunction of this enzyme.

NDUFB9 has also been shown to be involved in the production of other metabolites, such as FADH2 and succinate, which have also been linked to the development of certain diseases. For example, individuals with the genetic disorder, G6PD deficiency (G6PD), have defective NADH Oxidase, leading to the production of toxic intermediates that can cause damage to the cells.

NDUFB9 has also been shown to be a potential biomarker for certain diseases. For example, individuals with

Protein Name: NADH:ubiquinone Oxidoreductase Subunit B9

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed to be not involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

The "NDUFB9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFB9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets